Related Experiment Video
Updated: Jun 24, 2026
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model
Chun S Zuo1, Peter R Seoane, Morgane Thomsen
1Brain Imaging Center, McLean Hospital, Belmont, Massachusetts 02478, USA. chun@mclean.harvard.edu
Purpose:
To evaluate the feasibility of using manganese-based MR imaging contrast agent EVP-ABD to detect diffuse liver disease in an established rat hepatitis model.
Materials And Methods:
Hepatitis was induced by administration of CCl(4) in corn oil vehicle to rats intraperitoneally. MR images were acquired on a 3T scanner using a volume coil approximately 36 hours after the administration of CCl(4). EVP-ABD was administered via a tail vein at a dose of 10 mumol/kg. Multi-TI turboflash images were acquired to evaluate liver R1 (=1/T1) values before and after the EVP-ABD administration. Eighteen rats received various doses of CCl(4) and completed pre- and postcontrast MRI scans and liver histologic evaluation.
Results:
The liver R1 after the EVP-ABD administration and the change of the liver R1 before and after the administration, DeltaR1, show significant correlations with the CCl(4) dose. A significant correlation was also found between the histologic scores and the CCl(4) doses despite known variability in the relationship of CCl(4) dose to histology. A significant correlation was found between the histologic score and DeltaR1.
Conclusion:
Our results indicate that EVP-ABD-enhanced MRI can detect diffuse liver disease generated by CCl(4) based on the significant correlation between proton R1 in liver following EVP-ABD and the CCl(4) doses as well as the histologic scores.
Insights
Manganese-based MRI contrast agent EVP-ABD effectively detects diffuse liver disease in rats. Enhanced MRI signals correlated significantly with disease severity, showing promise for diagnosing liver conditions.
Area of Science:
- Magnetic Resonance Imaging (MRI)
- Hepatitis Research
- Contrast Agent Development
Background:
- Diffuse liver disease diagnosis remains challenging.
- Novel imaging techniques are needed for accurate assessment.
- Manganese-based contrast agents offer potential for enhanced MRI.
Purpose of the Study:
- To assess the feasibility of using EVP-ABD, a manganese-based MRI contrast agent, for detecting diffuse liver disease.
- To evaluate EVP-ABD's efficacy in a rat model of carbon tetrachloride (CCl4)-induced hepatitis.
- To correlate MRI findings with histological assessments of liver damage.
Main Methods:
- Hepatitis was induced in rats using intraperitoneal CCl4 administration.
- MRI scans were performed on a 3T scanner before and after EVP-ABD administration.
- Liver R1 values and changes (DeltaR1) were analyzed and correlated with CCl4 dose and histology.
Main Results:
- Liver R1 values and DeltaR1 showed significant correlation with CCl4 dose.
- Histological scores correlated significantly with CCl4 doses.
- A significant correlation was observed between histological scores and DeltaR1.
Conclusions:
- EVP-ABD-enhanced MRI can detect CCl4-induced diffuse liver disease in rats.
- The correlation between liver proton R1 post-EVP-ABD and CCl4 dose/histology supports its diagnostic potential.
- This study highlights EVP-ABD's promise as an MRI contrast agent for liver disease detection.
